A new method to engineer enzymes for chemical reactions in pharmaceuticals.
Bio-Click: A cell-free high-throughput platform for the engineering of enzymatic group transfer reactions
This study is working on a new way to quickly create and test special proteins that help make medicines better, which could lead to more effective treatments for patients like you.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Invizyne Technologies, INC. NIH-funded |
| Lab location | 1 site (Monrovia, UNITED STATES) |
| Project ID | NIH-11064718 on NIH RePORTER |
What this research studies
This research focuses on developing a high-throughput platform that allows for the rapid engineering of enzymes used in important chemical reactions for pharmaceuticals. By utilizing a cell-free protein synthesis system combined with advanced mass spectrometry, the project aims to create and test numerous enzyme variants efficiently. Patients may benefit from improved drugs that are more effective and have better properties due to the enhanced chemical processes being studied. The research specifically targets the engineering of enzymes that can modify natural and synthetic compounds, potentially leading to better therapeutic options.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals who require advanced pharmaceutical treatments or those with conditions that could be improved by novel drug formulations.
Not a fit: Patients who are not seeking new pharmaceutical treatments or those with conditions that do not respond to chemical modifications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer pharmaceuticals.
How similar studies have performed: Other research in synthetic biology and enzyme engineering has shown promising results, indicating that this approach could lead to significant advancements in drug development.
Where this research is happening
Monrovia, UNITED STATES
- Invizyne Technologies, INC. — Monrovia, United States (Active)
Researchers
- Principal investigator: Billingsley, John Martin — Invizyne Technologies, INC.
- Study coordinator: Billingsley, John Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.